Practice Areas
Cynthia Mazareas has more than 30 years of experience in serving as a trusted adviser to companies in the life sciences industry. She applies her deep knowledge to provide strategic business counsel to boards, management teams and in-house counsel, representing high-growth private and public companies in day-to-day corporate matters and helping companies navigate through complex business transactions. Ms. Mazareas is Chambers recognized, named in Best Lawyers in America for biotechnology and life sciences, and has been named a Life Sciences Star by LMG Life Sciences.
Ms. Mazareas has counseled numerous privately held and publicly traded life sciences companies throughout their lifecycle. Representative clients have included Agios Pharmaceuticals, Auron Therapeutics, AVEO Pharmaceuticals, Beam Therapeutics, Bectas Therapeutics, Cardurion Therapeutics, Cue Biopharma, Curis, IMARA, Mediar Therapeutics, Roshon Therapeutics, Schrödinger, Syros Pharmaceuticals, Translate Bio, Volastra Therapeutics and Xilio Therapeutics.
Clients rely on her combination of industry knowledge, legal experience and business acumen. One interviewed by Chambers described her as “substantive, diligent, bright and technically strong”, and another told Chambers, “Ms. Mazareas is a very real gold-standard attorney for companies in life sciences.”
Ms. Mazareas is also dedicated to using her skills to provide legal advice to organizations that are doing impactful work in the community. She represents MENTOR: The National Mentoring Partnership, an organization that aims to fuel the quality and quantity of mentoring relationships for young people and to close the mentoring gap for the one in three young people growing up without this critical support. She also provides advice to Bridge Over Troubled Waters, Boston’s foremost agency providing life-changing services for homeless, runaway and at-risk youth.
Experience
FINANCINGS
Agios Pharmaceuticals, a biopharmaceutical company pioneering therapies in the field of cellular metabolism, in its initial public offering, side-by-side strategic private placements and numerous subsequent follow-on offerings for aggregate gross proceeds of approximately $1.75 billion
Arsanis, a biopharmaceutical company focused on developing monoclonal antibodies for infectious diseases, in its $46 million initial public offering
Asylia Therapeutics, Inc., a biotechnology company, in its $7.5 million Series A financing
Auron Therapeutics, an oncology company, in its approximately $15 million Series Seed financing, its $48 million Series A financing and its $55 million Series B financing
AVEO Oncology, a commercial pharmaceutical company, in its initial public offering of nearly $90 million, and several subsequent follow-on public offerings and private placements
Beam Therapeutics, a biotechnology company conducting research in the field of gene therapies and genome editing, in its $500 million at-the-market offering and its $500 million follow-on underwritten public offering
BlinkBio Inc., a developer of drug conjugate therapies designed to facilitate the treatment of cancer, in its approximately $12 million Series A financing; and its $12 million Series B financing
Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of injectable biologics, in its $30 million private placement and underwritten offerings of $30 million
Curis, a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, in several financings, including recent follow-on public and registered direct offerings for aggregate proceeds of up to $530 million, as well as successive royalty financings to leverage an approved product
Denali Therapeutics, a biotechnology company focused on therapies for neurodegenerative and lysosomal storage diseases, in its $217 million Series A financing; and approximately $122 million Series B financing
IMARA, a clinical-stage biopharmaceutical company developing and commercializing, in its $86.5 million initial public offering and subsequent $50 million follow-on public offering
Infinity Pharmaceuticals, a clinical-stage biotechnology company, in public offerings with aggregate proceeds of $172 million, in its reverse merger/going public transaction, and its royalty sale of an FDA approved product to HealthCare Royalty Partners
KEW Group, a personalized oncology management company, in its venture capital financings
Larkspur Biosciences, a developer of cancer immunotherapies, in its $5.5 million Series Seed financing
Mediar Therapeutics, a clinical-stage company advancing first-in-class therapies to halt fibrosis progression, in its $85 million Series A financing and its $76 million Series B financing
Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, in its follow-on public offerings with aggregate proceeds of approximately $510 million
Schrödinger, a developer of a physics-based computational platform that enables discovery of novel molecules for drug development, in its initial public offering and subsequent follow-on public offering for aggregate gross proceeds of approximately $579 million, along with its prior Series E financing round led by WuXi AppTec and the Bill & Melinda Gates Foundation for aggregate gross proceeds of approximately $110 million
Syros Pharmaceuticals, a biopharmaceutical company, in its initial public offering and subsequent PIPEs, follow-on offerings and side-by-side strategic private placements for aggregate gross proceeds of approximately $373 million
Translate Bio, a clinical-stage mRNA therapeutics company, in its initial public offering and subsequent PIPE and follow-on offerings, for aggregate gross proceeds of approximately $376 million, and in a $125 million strategic equity investment by collaborator Sanofi Pasteur
Tvardi Therapeutics, a clinical-stage biopharmaceutical company developing treatments for fibrosis-driven diseases, in its $9 million Series A financing and its $74 million Series B financing
Volastra Therapeutics, a drug-discovery company specializing in new cancer treatments, in its $44 million Series Seed financing and $60 million Series A financing
Xilio Therapeutics, a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies, in its initial public offering with aggregate gross proceeds of approximately $130 million, its prior Series C cross-over financing for proceeds of approximately $95 million and its underwritten offering of pre-funded and Series A, B and C warrants with aggregate proceeds of up to $150 million
STRATEGIC TRANSACTIONS
Achillion Pharmaceuticals, a biotechnology company, in its $225 million strategic equity investment by Johnson & Johnson Innovation-JJDC, Inc., JJDC's subsequent secondary underwritten public offering, and Achillion's registered direct offering with a privately-owned hedge fund sponsor
Arsanis, a biopharmaceutical company, in its merger with X4 Pharmaceuticals
AVEO Oncology, a commercial-stage biopharmaceutical company, in its sale to LG Chem for approximately $566 million
IMARA, a clinical-stage biopharmaceutical company, in its sale of assets to Cardurion Pharmaceuticals and its subsequent merger with Enliven Therapeutics
Infinity Pharmaceuticals, a clinical-stage biotechnology company, in its proposed merger with MEI Pharma, as well as in its strategic equity transactions with Purdue Pharma, and Purdue Pharma's subsequent $450 million secondary underwritten public offering
Mediar Therapeutics, a clinical-stage company advancing first-in-class therapies to halt fibrosis progression, in its global licensing agreement with Lilly
Syros Pharmaceuticals, a biopharmaceutical company, in its acquisition of Tyme Technologies for $60 million
